Jean-Yves Douillard MD, PhD
Professor Emeritus, Medical Oncology, University of Nantes; Senior Advisor, Integrated Centers of Oncology (ICO), Nantes, FranceDr. Jean-Yves Douillard is a leading international expert in lung cancer and gastrointestinal oncology, and, over the course of a long career, he has held a number of leadership positions, including at the University of Nantes, where he was Professor in Medical Oncology, and at the Integrated Centers of Oncology (ICO) in Nantes, as Head of the Medical Oncology Department and later as Director of Clinical and Translational Research. He has also held senior ESMO positions, serving as Educational Committee Chair and as a member of the Executive Board.
Throughout his career, Dr. Douillard has led clinical trials in lung cancer and gastrointestinal tumors and has investigated targeted therapies, publishing his work in leading scientific journals. His clinical interests also include early drug development and translational research.
Currently, Dr. Doullard is serving as Senior Advisor in early clinical trial research at the Integrated Centers of Oncology.
Recent Contributions to PracticeUpdate:
- Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer
- First-Line Nivolumab + Ipilimumab Combined With Two Cycles of Chemotherapy in NSCLC
- 5-Year Outcomes With Nivolumab vs Docetaxel in Previously Treated NSCLC
- Durvalumab Therapy Following Chemoradiation vs Chemoradiation Alone in Patients With Stage III NSCLC
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- Key Takeaways From ESMO: Updates on Small-Cell Lung Cancer
- Key Takeaways From ESMO: Adjuvant and Neoadjuvant Therapy for NSCLC
- Pembrolizumab vs Single-Agent Chemotherapy for Advanced Pretreated Malignant Pleural Mesothelioma
- KRASG 12C Inhibition With Sotorasib in Advanced Solid Tumors
- New Approaches to Cancer Treatment in Select Patient Groups